Medical Doctor Program year 2022 Reported 2021–2022 Source: CMS Open Payments, 2026 publication

Heriberto Acosta

Neurology San Juan, PR Medical Doctor

NPI 1194895045 CMS profile 1137697

255 Calle Manuel Domenech, San Juan, PR 00918

Open in the dashboard

General payments

$68

2 records reported · program years 2021–2022

Research payments

$0

Paid to them · None reported · program years 2021–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Heriberto Acosta of San Juan, PR is reported in the CMS Open Payments database as having received $68 across 2 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 10th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $25 1
2021 General $43 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Heriberto Acosta
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Heriberto Acosta were reported at $0. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Heriberto Acosta Neurology median Middle half National median
2019 $0 $474 $118–$2,177 $163
2020 $0 $367 $82–$2,309 $114
2021 $43 $438 $104–$2,547 $132
2022 $25 $442 $103–$2,388 $149
2023 $0 $464 $119–$2,312 $160
2024 $0 $468 $119–$2,323 $164
2025 $0 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2021–2022
  1. Biogen, Inc. $43 1 payment
  2. AbbVie, Inc. $25 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2022
  1. Education $43 1 payment
  2. Food and Beverage $25 1 payment
Products named General payments · program years 2021–2022
  1. ADUHELM $43 1 payment
  2. OZURDEX $25 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 93 drugs

Part D claims

19,686

Median for Neurology: 833

Drug cost

$483,742

Median for Neurology: $202,670

Branded share of claims

17.2%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Memantine Hcl Generic 4,022 $69,801
Rivastigmine Rivastigmine Tartrate Brand 1,218 $59,480
Rivastigmine Generic 357 $44,627
Galantamine Er Galantamine Hbr Brand 400 $32,416
Galantamine Hbr Generic 525 $29,050
Omega-3 Acid Ethyl Esters Generic 381 $24,817
Memantine Hcl Er Memantine Hcl Brand 282 $22,136
Donepezil Hcl Generic 1,224 $17,247
Bupropion Xl Bupropion Hcl Brand 466 $11,069
Famotidine Generic 1,066 $10,165

The 10 drugs with the highest cost, of 93 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 10 billing codes

Paid by Medicare

$56,870

Medicare's payments for the services billed

Medicare patients

187

Average age 80

Services billed

519

118 women, 69 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 74%
Alzheimer's or dementia 65%
Arthritis 49%
Depression 37%
Chronic kidney disease 32%
Osteoporosis 26%
Ischemic heart disease 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

2 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Puerto Rico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record